1
|
Boğa C, Asma S, Leblebisatan G, Şen N, Tombak A, Demiroğlu YZ, Yeral M, Akın Ş, Yeşilağaç H, Habeşoğlu MA, Arıboğan A, Kasar M, Korur A, Özdoğu H. Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals. Ann Hematol 2021; 100:2195-2202. [PMID: 34032899 PMCID: PMC8144274 DOI: 10.1007/s00277-021-04549-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/01/2021] [Indexed: 12/04/2022]
Abstract
It is highly expected that COVID-19 infection will have devastating consequences in sickle cell disease (SCD) patients due to endothelial activation and decreased tissue and organ reserve as a result of microvascular ischemia and continuous inflammation. In this study, we aimed to compare the clinical course of COVID-19 in adult SCD patients under the organ injury mitigation and clinical care improvement program (BASCARE) with healthcare professionals without significant comorbid conditions. The study was planned as a retrospective, multicenter and cross-sectional study. Thirty-nine SCD patients, ages 18 to 64 years, and 121 healthcare professionals, ages 21 to 53, were included in the study. The data were collected from the Electronic Health Recording System of PRANA, where SCD patients under the BASCARE program had been registered. The data of other patients were collected from the Electronic Hospital Data Recording System and patient files. In the SCD group, the crude incidence of COVID-19 was 9%, while in healthcare professionals at the same period was 23%. Among the symptoms, besides fever, loss of smell and taste were more prominent in the SCD group than in healthcare professionals. There was a significant difference between the two groups in terms of development of pneumonia, hospitalization, and need for intubation (43 vs 5%, P < 0.00001; 26 vs 7%, P = 0.002; and 10 vs 1%, P = 0.002, respectively). Prophylactic low molecular weight heparin and salicylate were used more in the SCD group than in healthcare professionals group (41 vs 9% and 28 vs 1%; P < 0.0001 for both). The 3-month mortality rate was demonstrated as 5% in the SCD group, while 0 in the healthcare professionals group. One patient in the SCD group became continously dependent on respiratory support. The cause of death was acute chest syndrome in the first case, hepatic necrosis and multi-organ failure in the second case. In conclusion, these observations supported the expectation that the course of COVID-19 in SCD patients will get worse. The BASCARE program applied in SCD patients could not change the poor outcome.
Collapse
Affiliation(s)
- Can Boğa
- Department of Hematology, Sickle Cell Unit and Adana Adult Bone Marrow Transplantation Center, Baskent University School of Medicine, Ankara, Turkey.
| | - Süheyl Asma
- Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey
| | - Göksel Leblebisatan
- Department of Pediatric Hematology, Cukurova University School of Medicine, Adana, Turkey
| | - Nazan Şen
- Department of Pulmonology, Baskent University School of Medicine, Ankara, Turkey
| | - Anıl Tombak
- Department of Hematology, Mersin University, Mersin, Turkey
| | - Yusuf Ziya Demiroğlu
- Department of Infectious Disease, Baskent University School of Medicine, Ankara, Turkey
| | - Mahmut Yeral
- Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Şule Akın
- Department of Anesthesiology and Reanimation, Baskent University School of Medicine, Ankara, Turkey
| | - Hasan Yeşilağaç
- Department of Emergency Medicine and Traumatology, Baskent University School of Medicine, Ankara, Turkey
| | - Mehmet Ali Habeşoğlu
- Department of Pulmonology, Baskent University School of Medicine, Ankara, Turkey
| | - Anış Arıboğan
- Department of Anesthesiology and Reanimation, Baskent University School of Medicine, Ankara, Turkey
| | - Mutlu Kasar
- Department of Hematology, Sickle Cell Unit and Adana Adult Bone Marrow Transplantation Center, Baskent University School of Medicine, Ankara, Turkey
| | - Aslı Korur
- Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey
| | - Hakan Özdoğu
- Department of Hematology, Sickle Cell Unit and Adana Adult Bone Marrow Transplantation Center, Baskent University School of Medicine, Ankara, Turkey
| |
Collapse
|
2
|
Buyukkurt N, Kozanoğlu I, Korur AP, Asma S, Yeral M, Solmaz S, Kandemir F, Gereklioglu C, Sariturk C, Boga C, Ozdogu H. Comparative efficacy in red blood cell exchange transfusions with different apheresis machines in patients with sickle cell disease. Indian J Hematol Blood Transfus 2018; 34:495-500. [PMID: 30127560 DOI: 10.1007/s12288-017-0898-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Accepted: 10/30/2017] [Indexed: 11/26/2022] Open
Abstract
The purpose of this study is to compare the efficacy and side effects of two red blood cell exchange (RBCX) transfusion systems in sickle cell disease (SCD). The data is collected retrospectively from the January 2010 to March 2015. 447 RBCX transfusions were performed to 165 patients. Side effects, clinical and technical efficacy were compared in between procedures with Cobe Spectra (CS) and Spectra Optia (SO) systems. Furthermore a subgroup analyses was performed for 40 patients who had RBCX transfusions with both system at least two times. Vasoocclusive crises, preoperative period and foot ulcers (49.6, 13, and 15.2% respectively) were the common indications of RBCX transfusion. While the levels of post-RBCX HbS and the actual fraction of cells remaining (FCRa) were found significantly higher in the SO compared to CS system (p = 0.018 and p = 0.016 respectively), the rate of targeted hemoglobin S (HbS) levels (< 30%) were same in both. The length of procedure and replacement volume were significantly lower in SO compared to CS system (p = 0.025 and 0.044 respectively). Subgroup analyses of 40 patients did not reveal any statistically significant differences regarding post-procedure HbS levels, FCRa levels, replacement volume and procedure duration. The inter-rater correlation coefficient for FCRa was calculated to be 0.82. Serious adverse reactions were not observed from either system. Both systems are efficiently achieved the targeted post-procedure HbS level. The recently introduced SO apheresis system is as effective and safe as the CS system, which has been used for all indications of SCD for years.
Collapse
Affiliation(s)
- Nurhilal Buyukkurt
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Ilknur Kozanoğlu
- 2Department of Physiology, Baskent University School of Medicine, Ankara, Turkey
| | - Asli Pan Korur
- 3Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey
| | - Suheyl Asma
- 3Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey
| | - Mahmut Yeral
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Soner Solmaz
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Fatih Kandemir
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Cigdem Gereklioglu
- 3Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey
| | - Cagla Sariturk
- 4Biostatistics Specialist, Adana Research and Training Center, Baskent University, Adana, Turkey
| | - Can Boga
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| | - Hakan Ozdogu
- 1Department of Hematology, Baskent University School of Medicine, Ankara, Turkey
| |
Collapse
|
3
|
Asma S, Kozanoglu I, Tarım E, Sarıturk C, Gereklioglu C, Akdeniz A, Kasar M, Turgut NH, Yeral M, Kandemir F, Boga C, Ozdogu H. Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy. Transfusion 2014; 55:36-44. [DOI: 10.1111/trf.12780] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Revised: 05/28/2014] [Accepted: 05/28/2014] [Indexed: 02/06/2023]
Affiliation(s)
- Suheyl Asma
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
- Department of Family Medicine; Baskent University Medical Faculty; Ankara Turkey
| | - Ilknur Kozanoglu
- Cell Collecting and Therapeutic Apheresis Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
- Department of Physiology; Baskent University Medical Faculty; Ankara Turkey
| | - Ebru Tarım
- Department of Obstetrics and Gynecology; Baskent University Medical Faculty; Ankara Turkey
| | - Cagla Sarıturk
- Biostatistics Specialist; Baskent University Adana Hospital; Ankara Turkey
| | - Cigdem Gereklioglu
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
- Department of Family Medicine; Baskent University Medical Faculty; Ankara Turkey
| | - Aydan Akdeniz
- Department of Hematology; Mersin University Medical Faculty; Mersin Turkey
| | - Mutlu Kasar
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
| | - Nurhilal H. Turgut
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
| | - Mahmut Yeral
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
| | - Fatih Kandemir
- Department of Family Medicine; Baskent University Medical Faculty; Ankara Turkey
| | - Can Boga
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
| | - Hakan Ozdogu
- Clinical Unit; Baskent University Adana Adult Bone Marrow Transplantation Center; Ankara Turkey
| |
Collapse
|